Daniel Mikol, MD, PhD, vice president of Neuroscience Development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.
Daniel Mikol, MD, PhD
Advertisement
Articles by Daniel Mikol, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Building the Next Era of ALS Clinical Research and Trials
2
Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD
3
Optimizing Treatment Selection and Moving Beyond the Plateau
4
CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis
5
